About Singlera Genomics
Singlera Genomics is a company based in Pudong (China) founded in 2014. Singlera Genomics has raised $288.65 million across 6 funding rounds from investors including Yangzhou Guojin Investment Group, Yangzhou Longchuan Holding Group and Junci Investment. Singlera Genomics operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Pudong, China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$288.65 M (USD)
in 6 rounds
-
Latest Funding Round
$13.75 M (USD), Series B
Jul 05, 2024
-
Investors
Yangzhou Guojin Investment Group
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Singlera Genomics
Singlera Genomics has successfully raised a total of $288.65M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $13.75 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Singlera Genomics
Singlera Genomics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Yangzhou Guojin Investment Group, Yangzhou Longchuan Holding Group and Junci Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on mid to early stage companies in hard technology and healthcare sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Linden Asset Group is established as an investment and innovation hub.
|
Locked | Locked | Locked |
Investor details for Singlera Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Singlera Genomics
Investment portfolio details for Singlera Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Singlera Genomics
Detailed financials for Singlera Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Singlera Genomics Comparisons
Peer comparison for Singlera Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Singlera Genomics
Singlera Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of Singlera Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Singlera Genomics
Complete news archive for Singlera Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Singlera Genomics
Singlera Genomics was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Singlera Genomics is headquartered in Pudong, China. It is registered at Pudong, Shanghai, China.
Singlera Genomics is a funded company, having raised a total of $288.65M across 6 funding rounds to date.
Singlera Genomics was founded in 2014 in Pudong, China, within the biotechnology sector. An NGS-based platform is operated to detect cancer through methylation haplotyping technology. Circulating tumor DNA (ctDNA) released from tumor cells is analyzed as biomarkers. The PanSeer assay is utilized to identify distinct tumor-specific methylation patterns in adjacent sites, allowing cancer detection up to four years before conventional methods.
Singlera Genomics's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
Singlera Genomics has 14 investors. Key investors include Yangzhou Guojin Investment Group, Yangzhou Longchuan Holding Group, Junci Investment, Forstone Capital, and Detong Capital.